Yanagihara Katsunori, Okada Makiko, Fukuda Yuichi, Imamura Yoshifumi, Kaneko Yukihiro, Ohno Hideaki, Higashiyama Yasuhito, Miyazaki Yoshitsugu, Tsukamoto Kazuhiro, Hirakata Yoichi, Tomono Kazunori, Kadota Jun-Ichi, Tashiro Takayoshi, Murata Ikuo, Kohno Shigeru
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences, Nagasaki, Japan.
Chemotherapy. 2004 Nov;50(5):260-4. doi: 10.1159/000081948. Epub 2004 Nov 3.
Quinupristin-dalfopristin (Q-D) is a mixture of quinupristin and dalfopristin, which are semisynthetic antibiotics of streptogramin groups B and A, respectively.
We compared the effect of Q-D to that of vancomycin (VCM) in murine models of hematogenous pulmonary infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and VCM-insensitive S. aureus (VISA).
Treatment with Q-D resulted in a significant decrease in the number of viable bacteria in the lungs of mice in an MRSA infection model [Q-D 100 mg/kg, Q-D 10 mg/kg, VCM and control (mean +/- SEM): 2.99 +/- 0.44, 6.38 +/- 0.32, 5.75 +/- 0.43 and 8.40 +/- 0.14 log10 CFU/lung, respectively]. Compared with VCM, high-dose Q-D significantly reduced the number of bacteria detected in the VISA hematogenous infection model [Q-D 100 mg/kg, Q-D 10 mg/kg, VCM and control (mean +/- SEM): 5.17 +/- 0.52, 7.03 +/- 0.11, 7.10 +/- 0.49 and 7.18 +/- 0.36 log10 CFU/lung, respectively]. Histopathological examination confirmed the effect of Q-D.
Our results suggest that Q-D is potent and effective in the treatment of MRSA and VISA hematogenous pulmonary infections.
